Last reviewed · How we verify
No Anticholinergic Deprescription
This is a deprescribing strategy that involves the discontinuation or reduction of anticholinergic medications in patients where they are no longer clinically indicated.
This is a deprescribing strategy that involves the discontinuation or reduction of anticholinergic medications in patients where they are no longer clinically indicated. Used for Reduction of anticholinergic medication burden in patients with polypharmacy, Prevention of anticholinergic-related adverse effects in older adults.
At a glance
| Generic name | No Anticholinergic Deprescription |
|---|---|
| Sponsor | Deepak K. Sarpal, M.D. |
| Modality | Small molecule |
| Therapeutic area | Geriatrics / Deprescribing / Polypharmacy Management |
| Phase | FDA-approved |
Mechanism of action
Anticholinergic deprescribing is a clinical intervention aimed at reducing exposure to anticholinergic drugs, which are associated with cognitive impairment, falls, and other adverse effects particularly in older adults. By systematically identifying and discontinuing unnecessary anticholinergic medications, this approach seeks to improve patient safety and reduce medication burden. This is a practice guideline or clinical protocol rather than a pharmacological agent.
Approved indications
- Reduction of anticholinergic medication burden in patients at risk for anticholinergic-related adverse effects
Common side effects
Key clinical trials
- Anticholinergic Deprescription in Schizophrenia (PHASE4)
- Medication Empowerment and Deprescription for Safety (MEDS) Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |